Literature DB >> 21481723

Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.

Amaury Paumier1, Mithra Ghalibafian, Anne Beaudre, Ivaldo Ferreira, Charlotte Pichenot, Taha Messai, Nathalie Athalie Lessard, Dimitri Lefkopoulos, Theodore Girinsky.   

Abstract

PURPOSE: To assess the clinical outcome of the involved-node radiotherapy (INRT) concept using modern radiation treatments (intensity-modulated radiotherapy [IMRT] or deep-inspiration breath-hold radiotherapy [DIBH) in patients with localized supradiaphragmatic Hodgkin lymphoma. METHODS AND MATERIALS: All but 2 patients had early-stage Hodgkin lymphoma, and they were treated with chemotherapy prior to irradiation. Radiation treatments were delivered using the INRT concept according to European Organization for Research and Treatment of Cancer guidelines. IMRT was performed with the patient free-breathing. For the adapted breath-hold technique, a spirometer dedicated to DIBH radiotherapy was used. Three-dimensional conformal radiotherapy was performed with those patients.
RESULTS: Fifty patients with Hodgkin lymphoma (48 patients with primary Hodgkin lymphoma, 1 patient with recurrent disease, and 1 patient with refractory disease) entered the study from January 2003 to August 2008. Thirty-two patients were treated with IMRT, and 18 patients were treated with the DIBH technique. The median age was 28 years (range, 17-62 years). Thirty-four (68%) patients had stage I - (I-IIA) IIA disease, and 16 (32%) patients had stage I - (I-IIB) IIB disease. All but 3 patients received three to six cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). The median radiation doses to patients treated with IMRT and DIBH were, respectively, 40 Gy (range, 21.6-40 Gy) and 30.6 Gy (range, 19.8-40 Gy). Protection of various organs at risk was satisfactory. Median follow-up was 53.4 months (range, 19.1-93 months). The 5-year progression-free and overall survival rates for the whole population were 92% (95% confidence interval [CI], 80%-97%) and 94% (95% CI, 75%-98%), respectively. Recurrences occurred in 4 patients: 2 patients had in-field relapses, and 2 patients had visceral recurrences. Grade 3 acute lung toxicity (transient pneumonitis) occurred in 1 case.
CONCLUSIONS: Our results suggest that patients with localized Hodgkin lymphoma can be safely and efficiently treated using the INRT concept and modern radiation treatment techniques such as IMRT and DIBH.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481723     DOI: 10.1016/j.ijrobp.2010.09.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study.

Authors:  Vitaliana DE Sanctis; Alice DI Rocco; Maria Christina Cox; Maurizio Valeriani; Francesca Perrone Congedi; Dimitri Anzellini; Maria Massaro; Gianluca Vullo; Giuseppe Facondo; Flavia DE Giacomo; Marco Alfò; Daniela Prosperi; Patrizia Pizzichini; Sabrina Pelliccia; Agostino Tafuri; Maurizio Martelli; Mattia Falchetto Osti
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

Review 3.  Role of modern radiation therapy in early stage Hodgkin's lymphoma: A young radiation oncologists' perspective.

Authors:  Andrea Riccardo Filippi; Pierfrancesco Franco; Patrizia Ciammella
Journal:  Rep Pract Oncol Radiother       Date:  2012-07-19

Review 4.  Proton therapy for Hodgkin lymphoma.

Authors:  Michael S Rutenberg; Stella Flampouri; Bradford S Hoppe
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 5.  ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Authors:  Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine
Journal:  Am J Clin Oncol       Date:  2016-12       Impact factor: 2.339

Review 6.  Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Mubarak M Al-Mansour; Turki M Al-Fayea; Meteb Al-Foheidi; Ali M Bayer; Osama A Elmasri
Journal:  Lung       Date:  2012-10-06       Impact factor: 2.584

Review 7.  Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Authors:  Andrea Riccardo Filippi; Mario Levis; Rahul Parikh; Bradford Hoppe
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 8.  Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.

Authors:  Victor J Gonzalez
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 9.  Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

Authors:  Stephanie A Terezakis; Yvette L Kasamon
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-29       Impact factor: 6.312

10.  A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design.

Authors:  Jayant S Goda; Shirly C Lewis; Siddartha Laskar; Sadhna Kannan; Nehal Khanna; Hasmukh Jain; Bhausaheb Bagal; Sridhar Epari
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.